RCM Trends: High-Cost Drugs and AI Adoption
Wolters Kluwer has identified key trends shaping Revenue Cycle Management. Providers are grappling with managing reimbursement for high-cost therapies like GLP-1s and gene therapies. Simultaneously, they are pushing to adopt AI and automation for efficiency, but with a focus on augmenting, not replacing, clinical expertise.
The surge in GLP-1 drug utilization for weight loss, with employer spending jumping nearly 300% from 2021 to 2023, presents a significant RCM challenge. Prescriptions often cost around $1,000 a month, and while many plans cover them for diabetes, coverage for obesity-only indications is less consistent. This disparity, coupled with improper use—a 2024 analysis showed 10% of patients on a GLP-1 for diabetes lacked a corresponding diagnosis—complicates reimbursement and prior authorization workflows. Gene therapies introduce an even greater level of financial complexity, with prices ranging from $373,000 to over $4.25 million for a single treatment. Zolgensma for spinal muscular atrophy costs $2.1 million per patient, while the recently approved Libmeldy carries a price tag of $4.25 million. Payers and providers must navigate novel payment models, such as staggered payments over several years or performance-based agreements where payment is tied to patient outcomes. The administrative burden of prior authorizations for these high-cost drugs is substantial, with the average physician completing 45 per week. An American Medical Association survey revealed that 94% of providers report these processes delay patient care. In response, 47% of physicians now rank automated administrative systems as a top investment priority to manage the increasing volume and complexity. AI is being adopted to manage these challenges, with the market for AI in healthcare RCM projected to grow from $25.7 billion in 2025 to over $180 billion by 2034. AI-powered platforms can automate prior authorization submissions, reduce coding errors, and predict claim denials before they happen. This can decrease avoidable denials by 10-20% and cut coder rework time by 20-30%. While 63% of healthcare providers have started using AI in their revenue cycle, only 15% have fully integrated it into their standard operations. Concerns about data security, accuracy, and the cost of implementation remain the primary barriers to wider adoption. The return on investment for RCM automation is becoming clearer. One mid-size hospital system that implemented a hybrid AI model for medical coding and billing saw a 40% reduction in denied claims and a 32% increase in coding efficiency within six months. For many organizations, the initial investment in AI technology pays for itself within 12-18 months through these efficiencies and reduced denial rates.
